Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 3.74B P/E - EPS this Y 1.10% Ern Qtrly Grth -
Income -133.09M Forward P/E -69.32 EPS next Y 59.90% 50D Avg Chg 1.00%
Sales 37.28M PEG - EPS past 5Y - 200D Avg Chg 63.00%
Dividend N/A Price/Book 15.68 EPS next 5Y - 52W High Chg -
Recommedations 3.00 Quick Ratio 4.38 Shares Outstanding 71.92M 52W Low Chg 248.00%
Insider Own 12.01% ROA -18.55% Shares Float 58.98M Beta 1.23
Inst Own 84.39% ROE -46.96% Shares Shorted/Prior 7.61M/6.92M Price 51.99
Gross Margin -92.76% Profit Margin - Avg. Volume 2,578,060 Target Price 52.00
Oper. Margin -353.17% Earnings Date Feb 27 Volume 1,995,469 Change 0.00%
About ChemoCentryx, Inc.

ChemoCentryx, Inc., a biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It offers TAVNEOS (avacopan), an orally administered selective C5aR inhibitor for the treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis. The company also develops TAVNEOS for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy, and lupus nephritis. In addition, it develops CCX559, an orally administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally administered inhibitor of the chemokine receptor known as CCR9, which has completed Phase I clinical trial for the treatment of inflammatory bowel disease. Further, the company has early-stage drug candidates that targets Th17 driven diseases and CCR6. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California. As of October 20, 2022, ChemoCentryx, Inc. operates as a subsidiary of Amgen Inc.

CCXI Chatroom

User Image amiral Posted - 23 hours ago

@Smoothoperator99 @Stocktor Hey dude, you don’t @Stocktor and I am not here and will never lick anybody’s ass. One thing I can tell about him is that he have made really good calls and he have really good expertise especially in biopharmas. I rode $CCXI with him and we made bunch of money. Because of his call I made 5x of my investment. He also called other for example $DRCT when it was at $2 and then it run up to $34. So if you seriously don’t know him don’t bash him. You make yourself like an idiot when you post stupid posts like these. Be sensible and reasonable.

User Image Steve_TheBull_Rogers Posted - 4 days ago

@Mitxu Examples $CCXI and $LABP Both i was in, both pre market PR to say being bought, x amount, term of deal and closing date

User Image Night_Owl_Biotech Posted - 1 week ago

$BCRX 's enterprise value ("EV") is 17% of total 10-year analyst consensus revenue estimates. This is roughly half the revenue multiples of peers $PRVB, $CCXI, $GBT & $GWPH when they were acquired (EV's at 32 to 38% of their respective total 10-year revenue estimates per management...as filed in the subsequent 14A/14D9 filings). BCRX's gross margins are higher than all 4. Because BCRX is leveraged, BCRX's market cap would be roughly 150% higher if acquired at these peer revenue multiples (BCRX debt data per Seeking Alpha). BCRX's debt obligations may be higher if liquidated. It has been 41 months since Orladeyo was approved. GBT & GWPH were acquired roughly 33 months after FDA approval. These data points are summarized on the attachment. This is not investment advice. We're only pointing out the math associated with this BCRX "what if." As always, it is also possible our math is wrong. We suggest you research for yourself.

User Image martindube Posted - 2 weeks ago

$CCXI got me the black S6. Not really worried about $TRKAQ and my RS7

User Image RamenLives Posted - 03/28/24

$CCXI $60

User Image Steve_TheBull_Rogers Posted - 03/27/24

$AKBA Just took a call with a friend in pharma. He said the likelihood is that sooner or later, CSL VIFOR will buy this out for a tender + additional share in their bio per count It's now a play like $CCXI

User Image Dmoney136 Posted - 03/27/24

$AKBA friendly reminder that $CCXI did the same thing before approval.

User Image Anxietyy Posted - 03/27/24

@Steve_TheBull_Rogers you remember the dip of $CCXI

User Image Dmoney136 Posted - 03/27/24

@Stockinvestor73 this was $CCXI before approval. Nice try.

User Image Dmoney136 Posted - 03/27/24

$AKBA this was $CCXI

User Image Dmoney136 Posted - 03/27/24

$AKBA stop loss raid, I remember $CCXI was crazy, dropped from 30 to like 22 and rebound within a few minutes.

User Image Steve_TheBull_Rogers Posted - 03/27/24

$AKBA So you've prob clocked a lot of shorts follow me and come into the bio plays on long in, One is here and you've prob noticed him. I actually welcome it as their short causes more to squeeze in binary event I had one reach out to me over a year ago to say he kept shorting $CCXI as I was long and he hated me, he kept shorting even after approval when it had move 20 bucks, he then got caught short on the buy out He lost his whole account. So shorts who follow me, welcome, the water is warm

User Image Grrrissom Posted - 4 weeks ago

@DailyStocksPicks "The sharp decline...is predominantly attributed to concerns...regarding a higher incidence of EARLY DEATHS in patients treated?!!" Sure not getting the same vibe from this as I did that made me buy $CCXI when an advisory panel got involved.

User Image printintendies Posted - 1 month ago

$AKBA they did a stop loss raid in AH the day before avacopan was approved for $CCXI. Expect the unexpected. If you expect it it’s not unexpected 😂

User Image NCpilot172 Posted - 1 month ago

@SPECTRAL1 SA is a joke. I remember a couple of months before $CCXI was bought out, they were running hit pieces along with tipranks bashing the company. The arguments were invalid and highly biased, not objective and true. I would never take any article seriously. You never know what the authors hidden motives are. Always trust your own DD and trust it only!

User Image Ohzipit Posted - 1 month ago

@eriklarsen my DD is just fine. $VKTX @ $10, $RNA @ $6, $CBAY @$8, $CCXI $14 I can go on and on.

User Image Call_Me_Put Posted - 1 month ago

$GERN A $1.5/$2 4/19 strangle could be a decent play. IV is way too high on weeklies. I also like the drugs odds at approval and will pick up some shares if the ADCOM recommends against approval. Last post-ADCOM clinical bio play I made was $CCXI. ADCOM voted against, stock dropped around 80%, gladly bought some shares and the FDA approved it six months later. Advisory committees are typically way more cautious than the FDA itself, just remember that.

User Image StillnessofBreath Posted - 1 month ago

$MCRB shares are being stolen! https://link.springer.com/article/10.1007/s40265-024-02006-7 Everyone loves to say ATM, but no one has a clue,ostensibly don’t read 10q 1. If atm, still super undervalued, at least you aren’t buying at $5 Either way this is more like $CCXI $PRVB where they dropped heavily after approval to accumulate before buyout announcement

User Image RamenLives Posted - 1 month ago

$CCXI Not try to plug anything, just looking for some feedback on what you CCXI veterans think of $AADI...

User Image Ohzipit Posted - 02/27/24

@harri_28 hang in there. Same analyst covers both at RJF. Has a strong buy rating and a price target of $50. He also covered $CBAY (just bought) and $CCXI (bought by $AMGN in 2022.

User Image benderok37 Posted - 2 months ago

$IFRX Market cap 80millions. In 2021, $AGEN paid $3.7 billions for $CCXI (Avacopan) How true is

User Image RamenLives Posted - 2 months ago

$IOVA feels like the day after the $ccxi approval...maybe we will see a crazy sp...something in the twenties???

User Image NCpilot172 Posted - 2 months ago

$CCXI Doing some work, look what popped up. Good ole Tavneos…..

User Image spyzinger Posted - 2 months ago

$VRNA This is exactly what happened in $CCXI as well prior to approval. Right about the same price too,

User Image newdmontheblock Posted - 2 months ago

@Cchan78 @Nikki7220 back when $CCXI was approved, their PR dropped Friday morning. No reason we can’t here either

User Image PotatoJoe Posted - 2 months ago

$CCXI What have we learned after more than a year and a half since the buyout? That buyouts are as rare as seeing a Joe Biden diaper accident in the news.

User Image Ohzipit Posted - 2 months ago

$RNA thought I would repost this most current RJF research dated 0/05/24. Strong Buy rated price target $71.00. Same analyst gave us $CCXI and $CBAY

User Image NEWBIGTECH Posted - 2 months ago

@Scooter0732 $ICU $ESPR $FEMY these 3 stocks should be winners this year. I have been in chat for years. Bought $CBAY and $CCXI same day and same year.

User Image NEWBIGTECH Posted - 2 months ago

$THAR This stock reminds me of $CBAY and $CCXI when I bought both. It has answers to disease management.

User Image Steve_TheBull_Rogers Posted - 2 months ago

$MCRB Who was in the $CCXI buy out with me? Had months of just up down up down then one morning news hit and we gapped up the buy out This and AMRN are my two BO targets of 2024 Im sure this one will be gone before Q2 finishes

Analyst Ratings
Stifel Hold Aug 10, 22
SVB Leerink Market Perform Aug 5, 22
HC Wainwright & Co. Neutral Aug 5, 22
Canaccord Genuity Hold Aug 5, 22
Raymond James Market Perform Aug 5, 22
Raymond James Strong Buy May 6, 22
Raymond James Strong Buy Nov 10, 21
JP Morgan Neutral Oct 11, 21
SVB Leerink Outperform Oct 11, 21
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Schall Thomas J. President and CEO President and CEO Aug 04 Option 14.28 130,000 1,856,400 2,523,352 08/08/22
Schall Thomas J. President and CEO President and CEO Aug 04 Sell 50.24 130,000 6,531,200 2,393,352 08/08/22
KANAYA SUSAN M EVP, CFO and Sec. EVP, CFO and Sec. Aug 04 Option 6.43 46,298 297,696 137,615 08/08/22
KANAYA SUSAN M EVP, CFO and Sec. EVP, CFO and Sec. Aug 04 Sell 50.17 46,298 2,322,771 91,317 08/08/22
Tyree James L Director Director Aug 04 Sell 50.22 10,000 502,200 9,138 08/08/22
Cappel Markus J. Chief Bus. Officer &.. Chief Bus. Officer & Treasurer Aug 04 Sell 50.22 7,564 379,864 87,658 08/08/22
Tyree James L Director Director Jun 09 Sell 25.94 3,863 100,206 19,138 06/13/22
Tyree James L Director Director May 20 Option 0.00 7,726 23,001 05/24/22
Parker Geoffrey M. Director Director May 20 Option 0.00 7,726 21,076 05/24/22
MCKINNELL HENRY A Director Director May 20 Option 0.00 7,726 72,749 05/24/22
Jain Rita EVP, Chief Medical O.. EVP, Chief Medical Officer May 20 Option 0.00 7,726 35,863 05/24/22
Parker Geoffrey M. Director Director May 02 Option 14.42 12,500 180,250 124,413 05/03/22
Jain Rita EVP, Chief Medical O.. EVP, Chief Medical Officer Mar 27 Option 0.00 5,251 28,137 03/29/22
FECZKO JOSEPH M Director Director Jan 21 Option 15.16 37,500 568,500 148,127 01/25/22
Tyree James L Director Director Dec 17 Option 13.52 37,500 507,000 52,775 12/21/21
Tyree James L Director Director Dec 17 Sell 34.59 37,500 1,297,125 15,275 12/21/21
Schall Thomas J. President and CEO President and CEO Dec 01 Option 12.29 45,936 564,553 2,354,816 12/03/21
Tyree James L Director Director May 24 Option 0 4,660 17,729 05/24/21
Parker Geoffrey M. Director Director Mar 08 Sell 57.62 31,910 1,838,654 12,690 03/08/21
Cappel Markus J. Chief Bus. Officer &.. Chief Bus. Officer & Treasurer Mar 03 Option 9.5 33,092 314,374 118,918 03/03/21
Cappel Markus J. Chief Bus. Officer &.. Chief Bus. Officer & Treasurer Mar 03 Sell 68.43 33,092 2,264,486 85,826 03/03/21
Edwards Thomas A. Director Director Mar 03 Sell 70.06 1,100 77,066 119,857 03/03/21
Kwan Pui San Principal Acctg Offi.. Principal Acctg Officer Mar 01 Option 10.31 3,347 34,508 6,579 03/01/21
Kwan Pui San Principal Acctg Offi.. Principal Acctg Officer Mar 01 Sell 68.49 3,347 229,236 3,232 03/01/21
Cappel Markus J. Chief Bus. Officer &.. Chief Bus. Officer & Treasurer Feb 11 Option 11.02 700 7,714 86,526 02/11/21
Cappel Markus J. Chief Bus. Officer &.. Chief Bus. Officer & Treasurer Feb 11 Sell 69.66 700 48,762 85,826 02/11/21
Cappel Markus J. Chief Bus. Officer &.. Chief Bus. Officer & Treasurer Feb 08 Option 11.02 9,625 106,068 93,246 02/08/21
Cappel Markus J. Chief Bus. Officer &.. Chief Bus. Officer & Treasurer Feb 08 Sell 67.37 9,625 648,436 85,826 02/08/21
Kwan Pui San Principal Acctg Offi.. Principal Acctg Officer Feb 08 Sell 65 3,347 217,555 3,232 02/08/21
Kwan Pui San Principal Acctg Offi.. Principal Acctg Officer Feb 08 Option 10.31 3,347 34,508 6,579 02/08/21
Edwards Thomas A. Director Director Feb 04 Sell 61 20,000 1,220,000 121,357 02/04/21
Cappel Markus J. Chief Bus. Officer &.. Chief Bus. Officer & Treasurer Jan 27 Option 11.02 1,375 15,152 87,201 01/27/21
Cappel Markus J. Chief Bus. Officer &.. Chief Bus. Officer & Treasurer Jan 27 Sell 67.03 1,375 92,166 85,826 01/27/21
Edwards Thomas A. Director Director Dec 29 Sell 61.34 25,000 1,533,500 141,357 12/29/20
Schall Thomas J. President and CEO President and CEO Dec 16 Option 14.31 28,772 411,727 2,286,176 12/16/20
Schall Thomas J. President and CEO President and CEO Dec 16 Sell 65.02 28,772 1,870,755 2,268,557 12/16/20
Kwan Pui San Principal Acctg Offi.. Principal Acctg Officer Dec 16 Option 8.39 51,550 432,505 45,825 12/16/20
Kwan Pui San Principal Acctg Offi.. Principal Acctg Officer Dec 16 Sell 65.04 51,550 3,352,812 3,232 12/16/20